CGRPlahendusi

CGRPlahendusi is a term used to describe a family of interventions that aim to modulate the calcitonin gene-related peptide (CGRP) pathway to prevent or treat migraine and related disorders. The word combines CGRP with lahendus, a word meaning "solution" in Estonian, and is used in some European scientific contexts to denote CGRP-based therapeutic strategies.

Categories within CGRPlahendusi include monoclonal antibodies that target CGRP or its receptor, small-molecule CGRP receptor antagonists (gepants), and emerging modalities such as peptide inhibitors or RNA-based approaches.

CGRP is a neuropeptide involved in vasodilation and nociceptive signaling in the trigeminovascular system. Inhibiting CGRP signaling can reduce the frequency and intensity of migraine attacks and may benefit patients who do not respond to traditional preventive therapies.

Clinical development has led to several approved agents and ongoing research. Monoclonal antibodies against CGRP or its receptor are approved for migraine prevention in many regions, while gepants are used for acute treatment and, in some cases, prevention. Access and cost vary by country.

Safety monitoring continues for long-term use, with common adverse events including injection-site reactions for antibodies and gastrointestinal or dizziness symptoms for gepants. Researchers are exploring long-term cardiovascular safety, broader indications, and personalized treatment approaches within the CGRPlahendusi framework.